| P50 | author | Nina Friis-Møller | Q47006501 |
| | Fiona C Lampe | Q62006742 |
| | Jennifer Hoy | Q62903098 |
| | Andrew N Phillips | Q87677848 |
| | Lewis Kuller | Q88077314 |
| | Erik Stroes | Q91016106 |
| P2093 | author name string | Russell Tracy | |
| | Daniel A Duprez | |
| | David A Cooper | |
| | INSIGHT SMART Study Group | |
| | James Otvos | |
| | Angelike P Liappis | |
| | Jacquie Neuhaus | |
| | Nick I Paton | |
| P2860 | cites work | Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 | Q24802369 |
| | Inflammatory and coagulation biomarkers and mortality in patients with HIV infection | Q28473903 |
| | CD4+ count-guided interruption of antiretroviral treatment | Q29619489 |
| | Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk | Q33330313 |
| | Lipoprotein particle subclasses, cardiovascular disease and HIV infection. | Q33639078 |
| | Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters | Q33952995 |
| | Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. | Q34582291 |
| | HIV-associated dyslipidaemia: pathogenesis and treatment | Q37018213 |
| | CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial | Q38404888 |
| | Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile | Q39549464 |
| | LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). | Q40317506 |
| | Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women | Q40628500 |
| | Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. | Q42671235 |
| | Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART. | Q43671590 |
| | Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial | Q44054640 |
| | Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? | Q44055963 |
| | Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study | Q44063976 |
| | Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation | Q44190311 |
| | CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial | Q44471772 |
| | Impact of HIV infection and HAART on serum lipids in men. | Q44473694 |
| | Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. | Q44492237 |
| | Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters | Q44517872 |
| | A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection | Q44896075 |
| | Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. | Q44973436 |
| | Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 |
| | Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial | Q45332825 |
| | Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. | Q45729419 |
| | Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients | Q46527117 |
| | Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study | Q46546975 |
| | Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. | Q46573953 |
| | Retrospective analysis of suspending HAART in selected patients with controlled HIV replication | Q46625899 |
| | Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. | Q51013164 |
| | Lipid concentrations in serum and EDTA-treated plasma from fasting and nonfasting normal persons, with particular regard to high-density lipoprotein cholesterol. | Q51647595 |
| | EDTA-plasma vs serum differences in cholesterol, high-density-lipoprotein cholesterol, and triglyceride as measured by several methods. | Q52881613 |
| | Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. | Q54036214 |
| | Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Q57181081 |
| | Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy | Q79291045 |
| | Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial | Q79946492 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 275-284 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy | |
| P478 | volume | 54 | |